Incannex Healthcare Inc. (IXHL)
NASDAQ: IXHL · Real-Time Price · USD
0.2033
-0.0058 (-2.77%)
At close: Jun 27, 2025, 4:00 PM
0.2090
+0.0057 (2.80%)
After-hours: Jun 27, 2025, 7:59 PM EDT
Incannex Healthcare Employees
Incannex Healthcare had 9 employees as of June 30, 2024. The number of employees increased by 6 or 200.00% compared to the previous year.
Employees
9
Change
6
Growth
200.00%
Revenue / Employee
$10,889
Profits / Employee
-$2,415,889
Market Cap
19.05M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 9 | 6 | 200.00% |
| Jun 30, 2021 | 3 | 1 | 50.00% |
| Jun 30, 2020 | 2 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IXHL News
- 4 days ago - Incannex Healthcare Expands Clinical Advisory Board to Support Obstructive Sleep Apnea Program with Appointment of Dr. Douglas B. Kirsch - GlobeNewsWire
- 10 days ago - Incannex achieves key milestone with database lock for RePOSA Phase 2 trial of IHL-42X - GlobeNewsWire
- 11 days ago - Incannex Healthcare Forms Joint Venture with Mind Medicine Australia to Expand Access to Psychedelic-Assisted Therapy - GlobeNewsWire
- 16 days ago - Incannex Healthcare Cancels All Outstanding Series A Warrants Following Strategic ATM Execution - GlobeNewsWire
- 25 days ago - Incannex Healthcare Inc. Expands IHL-42X Clinical Advisory Board with Appointments of Four Industry and Academic Leaders to Advance Obstructive Sleep Apnea (OSA) Program - GlobeNewsWire
- 4 weeks ago - Incannex Healthcare Inc. Advances IHL-42X RePOSA Trial to Phase 3 Following FDA Protocol Clearance - GlobeNewsWire
- 4 weeks ago - Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) 3Q 2025 - Newsfile Corp
- 4 weeks ago - Incannex Healthcare Inc. Enters Agreement to Cancel Remaining Series A Warrants, Eliminating Up to 347.2 Million Shares from Potential Dilution Ahead of IHL-42X Phase 2 Topline Results - GlobeNewsWire